Physician profile
Scott E Ewing
NPI 1760461800
$14,891.36
in general payments reported to CMS, 2019-2025
42 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,029 · 2020: $296 · 2021: $1,429 · 2022: $2,376 · 2023: $3,013 · 2024: $2,112 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,761.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,391.75 | 2021-2025 | Onyx Frontier, Symplicity G3, Micra |
| Boston Scientific Corporation | $2,295.01 | 2019-2025 | Avvigo Guidance System, Opticross 6, Synergy |
| Medtronic Vascular, INC. | $2,110.93 | 2019-2020 | |
| Abiomed | $1,188.44 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,019.54 | 2019-2025 | |
| Pfizer INC. | $949.58 | 2019-2025 | |
| Shockwave Medical, INC | $769.88 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $671.71 | 2019-2025 | Triclip, Allure Quadra, Na |
| Penumbra, INC. | $511.67 | 2019-2024 | Indigo System, Penumbra System |
| Astrazeneca Pharmaceuticals LP | $398.17 | 2019-2022 | |
| Biotronik INC. | $330.46 | 2019-2024 | Orsiro Mission |
| Janssen Pharmaceuticals, INC | $329.52 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $252.54 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $220.87 | 2019-2022 | |
| Cvrx, INC. | $216.88 | 2024-2025 | Barostim Neo System |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.